MRVIMaravai LifeSciences Holdings, Inc.
Price
+177%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, growth steady, the market undecided.
Maravai LifeSciences Holdings, Inc. (also referred to in this document as “Maravai,” “we,” “us,” “our” or “the Company”) is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Our customers include biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions and diagnostics companies.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Maravai LifeSciences Holdings, Inc. (MRVI) reported revenue of $51M in Q2 2026 (quarter ended Jun 30, 2026), up 8.5% from the same quarter a year earlier. That came with a gross margin of 40% and net loss of $12M. For the full year FY2025, revenue was $186M (−28% year on year) and net income −$131M. Its largest region in Q2 2026 was United States at $31M, 47% of the disclosed total, ahead of North America at 38%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Second quarter 2026 total revenue up 9% from prior year.Earnings release · press release
- Jun 3, 2026On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP …Material agreement entered · Form 8-K
- May 7, 2026First quarter 2026 total revenue up 41% from prior year.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $65.6MThe company’s own SEC segment disclosure.
- United States$30.9M47%
- North America$24.6M38%
- EMEA$6.1M9%
- Asia Pacific$3.7M6%
- Latin And Central America$193.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.